Petrova and her colleagues (20) recently showed that Prox1 promotes dysplasia in colonic adenomas and colorectal cancer (CRC) progression; loss of Prox1 does not prevent tumor initiation but instead impairs tumor progression. Here, PROX1 is linked to colorectal carcinoma.